shown a definitive survival benefit. 2,3 Photodynamic therapy (PDT) is a promising new treatment modality for nonresectable cholangiocarcinoma. Its benefits include symptomatic improvement and prolonged survival with relatively few complications. 2 With PDT, a photosensitizing agent is preferentially retained by the malignant tissue. Following laser activation at a distinct wavelength, toxic oxygen radicals induce apoptosis of malignant cells and cause tumor necrosis. 2-4 PDT has been reported to have a minimal side effect profile, with the most frequently encountered adverse effect being phototoxicity to the skin. 2 In the last few years we have seen the rise of cholangioscopyguided PDT, which allows better identification of tumor margins, permits targeted laser illumination, and aids in evaluating the response to therapy. 5,6 We now report our experience with PDT, in the treatment of cholangiocarcinoma over the past 6 years. (49%) showed Bismuth type IV, 22 (41%) showed Bismuth type III, and six (10%) showed Bismuth type I and II. Twenty patients (37%) received chemotherapy and radiation therapy, five (9%) received chemotherapy only; and one (2%) received radiation therapy only. Mean number of PDT sessions was 1.9±1.5 sessions (range, 1 to 9). Mean survival duration was 293±266 days (median, 190; range, 25 to 1,332). PDT related complications included three (5%) facial burn, three (5%) photosensitivity, and two (3%) rash. Kaplan-Meier analysis comparing the survival means of patients who received PDT and chemotherapy/radiation therapy (median survival 257 days; 95% confidence interval [CI], 166 to 528) versus who received PDT only (median survival 183 days; 95% CI, 129 to 224) showed no significant difference (log-rank p=0.20). Conclusions: PDT has a measurable impact on survival in unresectable cholangiocarcinoma but requires aggressive stenting posttherapy.